MQS Management LLC Acquires New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

MQS Management LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,416 shares of the biopharmaceutical company’s stock, valued at approximately $250,000.

Several other hedge funds have also recently bought and sold shares of the stock. Private Wealth Management Group LLC acquired a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the 1st quarter worth approximately $29,000. Sachetta LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $30,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $33,000. Finally, Gladius Capital Management LP bought a new stake in shares of Gilead Sciences in the fourth quarter worth $34,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on GILD. TD Cowen decreased their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Friday, April 26th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective for the company in a report on Monday, July 8th. Barclays dropped their target price on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a report on Monday, April 29th. Morgan Stanley decreased their price target on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Twelve analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $81.81.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $3.01 during mid-day trading on Thursday, reaching $76.51. 11,731,208 shares of the company were exchanged, compared to its average volume of 7,466,100. The stock has a market capitalization of $95.32 billion, a P/E ratio of 212.53, a P/E/G ratio of 3.04 and a beta of 0.18. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The company’s 50-day simple moving average is $67.61 and its 200-day simple moving average is $71.23. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the prior year, the firm earned $1.37 EPS. The business’s revenue was up 5.3% on a year-over-year basis. As a group, research analysts predict that Gilead Sciences, Inc. will post 3.72 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.